Literature DB >> 29651774

Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas.

Lan Yu1,2,3, Xun Tian1,2, Chun Gao1,2, Ping Wu1,2, Liming Wang1,2, Bei Feng1,2, Xiaomin Li1,2, Hui Wang1,2, Ding Ma4,5, Zheng Hu6,7.   

Abstract

Viral infections cause at least 10%-15% of all human carcinomas. Over the last century, the elucidation of viral oncogenic roles in many cancer types has provided fundamental knowledge on carcinogenetic mechanisms and established a basis for the early intervention of virus-related cancers. Meanwhile, rapidly evolving genome-editing techniques targeting viral DNA/RNA have emerged as novel therapeutic strategies for treating virus-related carcinogenesis and have begun showing promising results. This review discusses the recent advances of genome-editing tools for treating tumorigenic viruses and their corresponding cancers, the challenges that must be overcome before clinically applying such genome-editing technologies, and more importantly, the potential solutions to these challenges.

Entities:  

Keywords:  delivery method; genome-editing tools; off-target effect; tumorigenic virus; virus-related carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29651774      PMCID: PMC7088620          DOI: 10.1007/s11684-017-0572-1

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  104 in total

1.  FokI requires two specific DNA sites for cleavage.

Authors:  E S Vanamee; S Santagata; A K Aggarwal
Journal:  J Mol Biol       Date:  2001-05-25       Impact factor: 5.469

2.  Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains.

Authors:  J Smith; M Bibikova; F G Whitby; A R Reddy; S Chandrasegaran; D Carroll
Journal:  Nucleic Acids Res       Date:  2000-09-01       Impact factor: 16.971

3.  Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.

Authors:  Miguel A Martínez; Arantxa Gutiérrez; Mercedes Armand-Ugón; Julià Blanco; Mariona Parera; Jordi Gómez; Bonaventura Clotet; José A Esté
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

4.  Binding of two zinc finger nuclease monomers to two specific sites is required for effective double-strand DNA cleavage.

Authors:  Mala Mani; Jeff Smith; Karthikeyan Kandavelou; Jeremy M Berg; Srinivasan Chandrasegaran
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

Review 5.  Partitioning viral genomes in mitosis: same idea, different targets.

Authors:  Alison A McBride; Jaquelline G Oliveira; Maria G McPhillips
Journal:  Cell Cycle       Date:  2006-07-17       Impact factor: 4.534

6.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.

Authors:  S Philpott; B Weiser; K Anastos; C M Kitchen; E Robison; W A Meyer; H S Sacks; U Mathur-Wagh; C Brunner; H Burger
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 8.  CccDNA persistence during natural evolution of chronic VHB infection.

Authors:  Florin Alexandru Caruntu; Violeta Molagic
Journal:  Rom J Gastroenterol       Date:  2005-12

9.  Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance.

Authors:  Katia Zanier; Sebastian Charbonnier; Mireille Baltzinger; Yves Nominé; Danièle Altschuh; Gilles Travé
Journal:  J Mol Biol       Date:  2005-04-09       Impact factor: 5.469

10.  Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.

Authors:  Xiao-Feng Qin; Dong Sung An; Irvin S Y Chen; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-23       Impact factor: 11.205

View more
  1 in total

1.  An effective vaginal gel to deliver CRISPR/Cas9 system encapsulated in poly (β-amino ester) nanoparticles for vaginal gene therapy.

Authors:  Gang Niu; Zhuang Jin; Chong Zhang; Dan He; Xueqin Gao; Chenming Zou; Wei Zhang; Jiahui Ding; Bhudev C Das; Konstantin Severinov; Inga Isabel Hitzeroth; Priya Ranjan Debata; Xin Ma; Xun Tian; Qinglei Gao; Jun Wu; Zeshan You; Rui Tian; Zifeng Cui; Weiwen Fan; Weiling Xie; Zhaoyue Huang; Chen Cao; Wei Xu; Hongxian Xie; Hongyan Xu; Xiongzhi Tang; Yan Wang; Zhiying Yu; Hui Han; Songwei Tan; Shuqin Chen; Zheng Hu
Journal:  EBioMedicine       Date:  2020-07-22       Impact factor: 8.143

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.